Key result
Intra-arterial urokinase is linked to ~33% greater functional independence at two years versus aspirin.
Why the study?
Thrombolysis improves 3-month outcomes in ischemic stroke, but knowledge of its long-term effects is limited.
Does intra-arterial thrombolysis using urokinase improve long-term functional independence compared to aspirin in patients with ischemic stroke?
Cohort (n=291)
Does intra-arterial thrombolysis using urokinase improve long-term functional independence compared to aspirin in patients with ischemic stroke?
Intra-arterial thrombolysis with urokinase provides a sustained functional benefit over aspirin at 2 years in patients with ischemic stroke.
BACKGROUND AND PURPOSE: Thrombolysis has been shown to improve the 3-month outcome of patients with ischemic stroke, but knowledge of the long-term effect of thrombolysis is limited. METHODS: The present study compares the long-term outcome of stroke patients who were treated with intra-arterial thrombolysis (IAT) using urokinase with the outcome of patients treated with aspirin. The modified Rankin Scale (mRS) was used to assess the outcome; 173 patients treated with IAT and 261 patients treated with aspirin from the Bernese Stroke Data Bank were eligible for the study. A matching algorithm taking into account patient age and stroke severity on admission (as measured by the National Institute of Health Stroke Scale [NIHSS]) was used to assemble an IAT and an aspirin group. RESULTS: One hundred and forty-four patients treated with IAT and 147 patients treated with aspirin could be matched and included in the comparative analysis. The median NIHSS score was 14 in each group. At 2 years, 56% of the patients treated with IAT and 42% of the patients treated with aspirin achieved functional independence (mRS, 0 to 2; P=0.037). Clinical outcome was excellent (mRS, 0 to 1) in 40% of the IAT and in 24% of the aspirin patients (P=0.008). Mortality was 23% and 24%, respectively. CONCLUSIONS: The present study provides evidence for a sustained effect of IAT when assessed 2 years after the stroke.
No takes yet. Share an insight, caveat, or question.
Nedeltchev et al. (2006) conducted a cohort in Ischemic stroke (n=291). Intra-arterial thrombolysis (IAT) using urokinase vs. Aspirin was evaluated on Functional independence (modified Rankin Scale, 0 to 2) at 2 years (p=0.037). Intra-arterial thrombolysis using urokinase was associated with higher functional independence at 2 years compared to aspirin (56% vs 42%, P=0.037) in matched patients with ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: